Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.

Autor: Johansson P; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany.; Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany., Alig S; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA., Richter J; Department of Hematopathology, University Hospital Schleswig-Holstein, Kiel, Germany., Hanoun C; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany., Rekowski J; Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Dürig J; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., de Jong D; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Klapper W; Department of Hematopathology, University Hospital Schleswig-Holstein, Kiel, Germany., Alizadeh AA; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.; Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, CA, USA., Dührsen U; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany. ulrich.duehrsen@uni-essen.de., Hüttmann A; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany.

Publikováno v: Annals of hematology [Ann Hematol] 2023 Dec; Vol. 102 (12), pp. 3445-3455. Date of Electronic Publication: 2023 Aug 11.

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.

Autor: Lynch RC; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Ujjani CS; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Poh C; Division of Medical Oncology, University of Washington, Seattle, WA., Warren EH; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Smith SD; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Shadman M; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Till B; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Raghunathan VM; Division of Medical Oncology, University of Washington, Seattle, WA., Alig S; Division of Oncology, Stanford University, Stanford, CA., Alizadeh AA; Division of Oncology, Stanford University, Stanford, CA., Gulhane A; Department of Radiology, University of Washington, Seattle, WA., Chen DL; Department of Radiology, University of Washington, Seattle, WA., Tseng Y; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.; Department of Radiation Oncology, University of Washington, Seattle, WA., Coye H; Division of Medical Oncology, University of Washington, Seattle, WA., Shelby M; Division of Medical Oncology, University of Washington, Seattle, WA., Ottemiller S; Division of Medical Oncology, University of Washington, Seattle, WA., Keo S; Division of Medical Oncology, University of Washington, Seattle, WA., Verni K; Division of Medical Oncology, University of Washington, Seattle, WA., Du H; Division of Medical Oncology, University of Washington, Seattle, WA., Vandermeer J; Division of Medical Oncology, University of Washington, Seattle, WA., Gaston A; Division of Medical Oncology, University of Washington, Seattle, WA., Rasmussen H; Division of Medical Oncology, University of Washington, Seattle, WA., Martin P; Division of Medical Oncology, University of Washington, Seattle, WA., Marzbani E; Division of Medical Oncology, University of Washington, Seattle, WA., Voutsinas J; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA., Gopal AK; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.

Publikováno v: Blood [Blood] 2023 May 25; Vol. 141 (21), pp. 2576-2586.

COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCL.

Autor: Sworder, B. J., Alig, S. K., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. Shahrokh, Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, J. Y., Baird, J. H., Carleton, M., Younes, S. F., Schroers‐Martin, J. G., Liu, C. L., Natkunam, Y., Majzner, R. G., Mackall, C. L., Miklos, D. B.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p214-216, 3p

Molecular Monitoring of Lymphomas.

Autor: Schroers-Martin JG; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu., Alig S; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu., Garofalo A; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu., Tessoulin B; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.; Current affiliation: Clinical Hematology Department, Nantes University Hospital, Nantes, France., Sugio T; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu., Alizadeh AA; Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California, USA; email: arasha@stanford.edu.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.; Stanford Cancer Institute, Stanford University, Stanford, California, USA.

Publikováno v: Annual review of pathology [Annu Rev Pathol] 2023 Jan 24; Vol. 18, pp. 149-180. Date of Electronic Publication: 2022 Sep 21.

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.

Autor: Kurtz DM; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.; Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Soo J; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Co Ting Keh L; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Alig S; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Chabon JJ; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.; Foresight Diagnostics, Aurora, CO, USA., Sworder BJ; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Schultz A; Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Jin MC; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Scherer F; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.; Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Garofalo A; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Macaulay CW; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Hamilton EG; Program in Cancer Biology, Stanford University, Stanford, CA, USA., Chen B; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.; Department of Genetics, Stanford University, Stanford, CA, USA., Olsen M; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Schroers-Martin JG; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA., Craig AFM; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Moding EJ; Department of Radiation Oncology, Stanford University, Stanford, CA, USA., Esfahani MS; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Liu CL; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA., Dührsen U; Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany., Hüttmann A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany., Casasnovas RO; Department of Hematology, Hopital F. Mitterrand, CHU Dijon and INSERM, Dijon, France., Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roschewski M; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wilson WH; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy., Rossi D; Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland., Diehn M; Stanford Cancer Institute, Stanford University, Stanford, CA, USA. diehn@stanford.edu.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. diehn@stanford.edu.; Department of Radiation Oncology, Stanford University, Stanford, CA, USA. diehn@stanford.edu., Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.; Stanford Cancer Institute, Stanford University, Stanford, CA, USA. arasha@stanford.edu.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2021 Dec; Vol. 39 (12), pp. 1537-1547. Date of Electronic Publication: 2021 Jul 22.